Last mentioned: Feb 24, 2026
First Approvals
Anticipated first wave of gene therapy approvals under the new streamlined framework.
Expected Finalization
Anticipated period for final guidance after public comment and review.
New System Proposed
FDA formally announces the proposed framework for customized drug approvals.
Quicker Path Formalized
Official rollout of the streamlined regulatory framework for gene therapy approvals.
Framework Formalized
FDA officially announces the 'plausible mechanism' framework for ultra-rare disease therapies.
Draft Guidance Issued
FDA releases draft guidance on using surrogate endpoints for gene therapy accelerated approval.
CBER Staffing Surge
FDA completes hiring of 100+ new reviewers dedicated to biologics and gene therapy.
START Pilot Launch
FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics (START) pilot program.
START Program
CBER launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.
START Pilot Program
FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.
ASO Guidance
FDA issues initial draft guidance for ASO products for ultra-rare diseases.
First Gene Therapy Approved
FDA approves Luxturna for a rare form of inherited vision loss.
The FDA has unveiled a proposed regulatory pathway designed to accelerate the approval of customized, patient-specific therapies for ultra-rare diseases. This initiative aims to shift from traditional population-based clinical trials to a data-driven model that supports individualized genomic medicine.
The FDA has officially introduced a streamlined regulatory pathway for gene therapies, allowing for accelerated approval based on 'plausible mechanisms' and biomarkers rather than traditional clinical outcomes. This landmark shift aims to fast-track treatments for ultra-rare diseases where traditional large-scale clinical trials are statistically impossible.
The FDA has launched a streamlined regulatory pathway designed to expedite the development and review of gene therapies, particularly for rare diseases. This initiative marks a significant shift toward using surrogate endpoints and flexible trial designs to bring life-saving treatments to market faster.